AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12150648 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 161
Study 12150648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 10497008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV), d4T, or NFV + d4T for 24 weeks, followed by triple therapy (NFV + reverse transcriptase inhibitors) for an additional 24 weeks
Number of subjects: 23
Study 10497008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV), d4T, or NFV + d4T
Number of subjects: 23
Study 8949803 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic impedance (TTI) measurements
Number of subjects: 10
Study 8949803 — intervention group
Group type: COMPARATOR
Intervention: Inductance band (IB) signals
Number of subjects: 10
Study 8949803 — intervention group
Group type: COMPARATOR
Intervention: Transient respiratory disturbance
Number of subjects: 10
Study 1918842 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate, 2 g b.i.d.
Number of subjects: 165
Study 1918842 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 150 mg twice daily
Number of subjects: 165
Study 1918842 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate, 2 g b.i.d. (in smokers)
Number of subjects: 165
Study 1918842 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 150 mg twice daily (in smokers)
Number of subjects: 165
Study 6123808 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin ('Glypressin') 2 mg every 6 hours
Number of subjects: 19
Study 6123808 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin 0.4 units/min IV infusion
Number of subjects: 19
Study 6123808 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin ('Glypressin')
Number of subjects: 19
Study 31626157 — intervention group
Group type: EXPERIMENTAL
Intervention: Terahertz-modulated infrared radiotherapy
Number of subjects: 92
Study 31626157 — intervention group
Group type: COMPARATOR
Intervention: Control group (disease-modifying anti-rheumatic drugs and therapeutic exercises)
Number of subjects: 92
Study 28947723 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rivaroxaban
Number of subjects: 3365
Study 28947723 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rivaroxaban
Number of subjects: 3365
Study 28947723 — intervention group
Group type: COMPARATOR
Intervention: 100 mg aspirin (ASA)
Number of subjects: 3365
Study 28947723 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (20 mg rivaroxaban, 10 mg rivaroxaban, 100 mg ASA)
Number of subjects: 3365
Study 24912653 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic transfusion of fresh-frozen plasma (FFP) at a dosage of 12 mL/kg
Number of subjects: 81
Study 24912653 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic transfusion of fresh-frozen plasma (FFP)
Number of subjects: 81
Study 25141526 — intervention group
Group type: EXPERIMENTAL
Intervention: LF‐rTMS
Number of subjects: 14
Study 25141526 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 14
Study 22747953 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line and second-line anti-tuberculosis drugs
Number of subjects: 5
Study 22747953 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin (SM) and Ofloxacin (OFX)
Number of subjects: 5
Study 22747953 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid and SM
Number of subjects: 5
Study 22747953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethionamide, Streptomycin (SM), and Ofloxacin (OFX)
Number of subjects: 5
Study 21163116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligustrazine plus chemotherapy
Number of subjects: 60
Study 21163116 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 60
Study 18269072 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivicaine
Number of subjects: 27
Study 18269072 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 27
Study 16248392 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m DTPA clearance rate
Number of subjects: 19
Study 16248392 — intervention group
Group type: COMPARATOR
Intervention: Spirometric parameters (VC, FVC, FEV1/FVC, FEF 25-75)
Number of subjects: 19
Study 16248392 — intervention group
Group type: COMPARATOR
Intervention: DLCO, DLCO/VA, T1/2 values of Tc-99m DTPA clearance
Number of subjects: 19
Study 16248392 — intervention group
Group type: EXPERIMENTAL
Intervention: DLCO/VA and T1/2 values of Tc-99m DTPA clearance
Number of subjects: 19
Study 16248392 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone levels
Number of subjects: 19
Study 12390160 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5%
Number of subjects: 64
Study 12390160 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.25%
Number of subjects: 64
Study 10445198 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic IOL (Alcon AcrySof)
Number of subjects: 120
Study 10445198 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel IOL (Bausch & Lomb Hydroview)
Number of subjects: 120
Study 10445198 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl methacrylate/hydroxyethyl methacrylate IOL (Mentor MemoryLens)
Number of subjects: 120
Study 10445198 — intervention group
Group type: EXPERIMENTAL
Intervention: Foldable silicone IOL (Pharmacia 920)
Number of subjects: 120
Study 7495922 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol maintenance
Number of subjects: 30
Study 7495922 — intervention group
Group type: COMPARATOR
Intervention: Placebo replacement
Number of subjects: 30
Study 2307735 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 24
Study 2307735 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 24
Study 7138720 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. morphine
Number of subjects: 56
Study 7138720 — intervention group
Group type: EXPERIMENTAL
Intervention: high-level extradural morphine
Number of subjects: 56
Study 7138720 — intervention group
Group type: EXPERIMENTAL
Intervention: low-level extradural morphine
Number of subjects: 56
Study 30119941 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intravenous hydromorphone
Number of subjects: 220
Study 30119941 — intervention group
Group type: COMPARATOR
Intervention: 1 g intravenous acetaminophen
Number of subjects: 220
Study 28943039 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific guides (PSG)
Number of subjects: 50
Study 28943039 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumentation (control)
Number of subjects: 50
Study 25438954 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 40
Study 25438954 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single‐site cholecystectomy (LSSC)
Number of subjects: 40
Study 25693331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower thoracic epidural analgesia (T group)
Number of subjects: 50
Study 18198642 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (WM) - non-steroid anti-inflammatory agents and slow acting medicine
Number of subjects: 397
Study 18198642 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) - basic remedy and syndrome differentiating medication
Number of subjects: 397
Study 18198642 — intervention group
Group type: COMPARATOR
Intervention: Comparison between CM and WM
Number of subjects: 397
Study 15473621 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 2.5 mg mL(‐1) 30 mL with epinephrine 5 microg mL(‐1)
Number of subjects: 0
Study 15473621 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 30 mL with epinephrine 5 microg mL(‐1)
Number of subjects: 0
Study 15473621 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Levobupivacaine and Normal saline)
Number of subjects: 0
Study 11090162 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal transplant patients
Number of subjects: 13
Study 11090162 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis patients
Number of subjects: 13
Study 11090162 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 13
Study 9212474 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal needles of gauge 26
Number of subjects: 584
Study 9212474 — intervention group
Group type: COMPARATOR
Intervention: Spinal needles of gauge 24 and 25
Number of subjects: 584
Study 9212474 — intervention group
Group type: EXPERIMENTAL
Intervention: All females (including C/S)
Number of subjects: 584
Study 9212474 — intervention group
Group type: COMPARATOR
Intervention: Non-obstetric females
Number of subjects: 584
Study 9212474 — intervention group
Group type: COMPARATOR
Intervention: Males
Number of subjects: 584
Study 8451781 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin loading dose of 3 mg/kg
Number of subjects: 166
Study 8451781 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin loading dose of 4 mg/kg for younger patients (<= 34 weeks gestational age)
Number of subjects: 166
Study 8451781 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean initial dose delivered was 2.41 mg/kg
Number of subjects: 166
Study 3766683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic extension
Number of subjects: 20
Study 3766683 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted extension
Number of subjects: 20
Study 3766683 — intervention group
Group type: COMPARATOR
Intervention: Resisted grasp
Number of subjects: 20
Study 3766683 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 31928690 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib in combination with fulvestrant
Number of subjects: 0
Study 31928690 — intervention group
Group type: COMPARATOR
Intervention: Pan-PI3K inhibitors
Number of subjects: 0
Study 28972411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dizziness Handicap Inventory (DHI) assessment
Number of subjects: 65
Study 26328497 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic rosuvastatin (RSV) for 24 weeks
Number of subjects: 0
Study 26328497 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipophilic pitavastatin (PTV) for 24 weeks
Number of subjects: 0
Study 26328497 — intervention group
Group type: COMPARATOR
Intervention: Both RSV and PTV
Number of subjects: 0
Study 23485015 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS targeting Wernicke's and right homologous sites
Number of subjects: 83
Study 23485015 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS targeting right homologous site (rW)
Number of subjects: 83
Study 23485015 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS targeting Wernicke's site (W)
Number of subjects: 83
Study 23485015 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 83
Study 22044287 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAM) 1.2 g by mouth daily
Number of subjects: 37
Study 22044287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 19825328 — intervention group
Group type: EXPERIMENTAL
Intervention: Film-coated tablets (2 x 12.5 mg diclofenac-K)
Number of subjects: 29
Study 19825328 — intervention group
Group type: COMPARATOR
Intervention: Sugar-coated tablet (1 x 25 mg diclofenac-K)
Number of subjects: 29
Study 19825328 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 29
Study 16715914 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% isoflurane
Number of subjects: 40
Study 16715914 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% isoflurane
Number of subjects: 40
Study 16715914 — intervention group
Group type: COMPARATOR
Intervention: Mask ventilation with isoflurane
Number of subjects: 40
Study 16715914 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 40
Study 15297095 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich liquid formula (Fortimel, 200 ml/day, 20 g protein/day)
Number of subjects: 60
Study 15297095 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich liquid formula (Fortimel, 200 ml/day, 20 g protein/day) + nandrolone decanoate (Deca-Durabol 25 mg i.m./3 weeks)
Number of subjects: 60
Study 15297095 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 60
Study 11465652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg/day)
Number of subjects: 2504
Study 9251163 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular or frozen yogurt (palatable food stimuli)
Number of subjects: 36
Study 9251163 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated food presentations
Number of subjects: 36
Study 8276045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholic acid (CA) 10 mg.kg‐1 per day for 3 months
Number of subjects: 6
Study 8276045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at the same dose after CA therapy
Number of subjects: 6
Study 8276045 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 6
Study 2880692 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of SMS 201-995 (2 mg) with 75 g of glucose
Number of subjects: 5
Study 2880692 — intervention group
Group type: COMPARATOR
Intervention: Control study (not specified)
Number of subjects: 5
Study 31539635 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial-specimen diversion technique (ISDT)
Number of subjects: 756
Study 31539635 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure
Number of subjects: 756
Study 31539635 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDT
Number of subjects: 756
Study 29723659 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea herbal consumed daily for 6 weeks
Number of subjects: 30
Study 29723659 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 27445866 — intervention group
Group type: EXPERIMENTAL
Intervention: GAÏA s‐face program (GAÏA arm)
Number of subjects: 40
Study 27445866 — intervention group
Group type: COMPARATOR
Intervention: RECOS program (RECOS arm)
Number of subjects: 40
Study 24975116 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustrated patient information leaflet (PIL)
Number of subjects: 0
Study 24975116 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 0
Study 22434324 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (2 mA for 20 min)
Number of subjects: 9
Study 22434324 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (2 mA for 1 min)
Number of subjects: 9
Study 20930652 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron gluconate (IG)
Number of subjects: 105
Study 20930652 — intervention group
Group type: COMPARATOR
Intervention: Iron polymaltose complex (IPC)
Number of subjects: 105
Study 18656053 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal sacrocolpopexy
Number of subjects: 322
Study 18656053 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimism
Number of subjects: 322
Study 16192518 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 10
Study 16192518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12814161 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17 levels in induced sputum of asthma patients
Number of subjects: 56
Study 12814161 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17 levels in induced sputum of chronic bronchitis patients
Number of subjects: 56
Study 12814161 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17 levels in induced sputum of COPD patients
Number of subjects: 56
Study 12814161 — intervention group
Group type: COMPARATOR
Intervention: Comparison of IL-17 levels in bronchial hyperreactivity group (asthmatics and CB patients)
Number of subjects: 56
Study 12814161 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17 levels in asthmatic patients with bronchial hyperreactivity
Number of subjects: 56
Study 12814161 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IL-17 levels with PC20
Number of subjects: 56
Study 10673514 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC plus pretreatment with ethinyl estradiol (EE(2))
Number of subjects: 328
Study 10673514 — intervention group
Group type: COMPARATOR
Intervention: FAC chemotherapy alone
Number of subjects: 328
Study 8857916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic transdermal therapy (17 beta‐estradiol 50 micrograms/d + medroxyprogesterone acetate 10 mg/d for 12 days per cycle)
Number of subjects: 120
Study 8857916 — intervention group
Group type: COMPARATOR
Intervention: Continuous oral therapy (17 beta‐estradiol 2 mg/d + norethisterone acetate 1 mg/d for 12 months)
Number of subjects: 120
Study 1537158 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) device
Number of subjects: 22
Study 1537158 — intervention group
Group type: COMPARATOR
Intervention: Postoperative splint
Number of subjects: 22
Study 6380067 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid and ethambutol, thrice weekly for 18 months
Number of subjects: 587
Study 6380067 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 587
Study 31797789 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery plus neck dissection
Number of subjects: 0
Study 29587148 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral approach (ad modum Watson)
Number of subjects: 28
Study 29587148 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach (ad modum Moore)
Number of subjects: 28
Study 29587148 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral approach
Number of subjects: 28
Study 27766771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (group U) - 20,000 U/kg/hour for the first hour, then 5,000 U/kg/hour until surgery conclusion
Number of subjects: 108
Study 27766771 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 108
Study 27766771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (group U)
Number of subjects: 108
Study 24480945 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical zipper
Number of subjects: 90
Study 24480945 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular Monocryl sutures
Number of subjects: 90
Study 22901031 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning and mastery course
Number of subjects: 69
Study 21147743 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs
Number of subjects: 0
Study 21147743 — intervention group
Group type: COMPARATOR
Intervention: No antiepileptic treatment
Number of subjects: 0
Study 17955358 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine 5 g IV bolus followed by 10 g/day IV infusion for 3 days
Number of subjects: 96
Study 17955358 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 15681529 — intervention group
Group type: EXPERIMENTAL
Intervention: Prinomastat 15 mg plus gemcitabine-cisplatin chemotherapy
Number of subjects: 362
Study 15681529 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine-cisplatin chemotherapy
Number of subjects: 362
Study 15681529 — intervention group
Group type: EXPERIMENTAL
Intervention: Prinomastat
Number of subjects: 362
Study 15681529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 12473441 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife care (n = 101)
Number of subjects: 194
Study 12473441 — intervention group
Group type: COMPARATOR
Intervention: Doctor care (n = 93)
Number of subjects: 194
Study 11907945 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (Livial) daily
Number of subjects: 40
Study 11907945 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogens (CEE, Premarin) plus sequential medroxyprogesterone acetate (MPA, Prodafem)
Number of subjects: 40
Study 11907945 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 8029587 — intervention group
Group type: EXPERIMENTAL
Intervention: High calorie diet (including Fresubin, a fluid nutrient formula)
Number of subjects: 30
Study 8029587 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 2488701 — intervention group
Group type: EXPERIMENTAL
Intervention: LEYTAS automated screening procedure
Number of subjects: 1500
Study 2488701 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-interaction classification
Number of subjects: 1500
Study 1093458 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 11
Study 1093458 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg meperidine
Number of subjects: 11
Study 1093458 — intervention group
Group type: COMPARATOR
Intervention: saline solution
Number of subjects: 11
Study 1093458 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine
Number of subjects: 11
Study 1093458 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 11
Study 30339720 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment
Number of subjects: 43
Study 28687677 — intervention group
Group type: EXPERIMENTAL
Intervention: HELP intervention (12-session programme)
Number of subjects: 174
Study 28687677 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 174
Study 28687677 — intervention group
Group type: EXPERIMENTAL
Intervention: HELP intervention
Number of subjects: 174
Study 28687677 — intervention group
Group type: COMPARATOR
Intervention: HELP intervention and Standard care (control)
Number of subjects: 174
Study 25847016 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg, two times a day for 3 days
Number of subjects: 18
Study 25847016 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen 100 mg, two times a day for 3 days
Number of subjects: 18
Study 25847016 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Nimesulide and Ketoprofen)
Number of subjects: 18
Study 22491708 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infusion analgesia (intermittent bolus intra-articular injection of ropivacaine, dexamethasone, and isepamicin until postoperative 48 hours)
Number of subjects: 40
Study 22491708 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 40
Study 22491708 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infusion analgesia
Number of subjects: 40